Literature DB >> 21353545

Structure-activity relationship study of 2,4-diaminothiazoles as Cdk5/p25 kinase inhibitors.

Joydev K Laha1, Xuemei Zhang, Lixin Qiao, Min Liu, Snigdha Chatterjee, Shaughnessy Robinson, Kenneth S Kosik, Gregory D Cuny.   

Abstract

Cdk5/n class="Gene">p25 has emerged as a principle therapeutic target for numerous acute and chronic neurodegenerative diseases, including Alzheimer's disease. A structure-activity relationship study of 2,4-diaminothiazole inhibitors revealed that increased Cdk5/p25 inhibitory activity could be accomplished by incorporating pyridines on the 2-amino group and addition of substituents to the 2- or 3-position of the phenyl ketone moiety. Interpretation of the SAR results for many of the analogs was aided through in silico docking with Cdk5/p25 and calculating protein hydrations sites using WaterMap. Finally, improved in vitro mouse microsomal stability was also achieved.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21353545      PMCID: PMC3062192          DOI: 10.1016/j.bmcl.2011.01.140

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  46 in total

1.  Effect of stereochemistry on the anti-HIV activity of chiral thiourea compounds.

Authors:  T K Venkatachalam; C Mao; Fatih M Uckun
Journal:  Bioorg Med Chem       Date:  2004-08-01       Impact factor: 3.641

2.  Role of the active-site solvent in the thermodynamics of factor Xa ligand binding.

Authors:  Robert Abel; Tom Young; Ramy Farid; Bruce J Berne; Richard A Friesner
Journal:  J Am Chem Soc       Date:  2008-02-12       Impact factor: 15.419

Review 3.  Kinase inhibitors as potential therapeutics for acute and chronic neurodegenerative conditions.

Authors:  G D Cuny
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

4.  Pyrazolo[3,4-b]quinoxalines. A new class of cyclin-dependent kinases inhibitors.

Authors:  Miguel A Ortega; María E Montoya; Belén Zarranz; Andrés Jaso; Ignacio Aldana; Sophie Leclerc; Laurent Meijer; Antonio Monge
Journal:  Bioorg Med Chem       Date:  2002-07       Impact factor: 3.641

5.  Structure and regulation of the CDK5-p25(nck5a) complex.

Authors:  C Tarricone; R Dhavan; J Peng; L B Areces; L H Tsai; A Musacchio
Journal:  Mol Cell       Date:  2001-09       Impact factor: 17.970

6.  Clubbed thiazoles by MAOS: a novel approach to cyclin-dependent kinase 5/p25 inhibitors as a potential treatment for Alzheimer's disease.

Authors:  Mahendra Ramesh Shiradkar; Kalyan Chakravarthy Akula; Varaprasad Dasari; Vijayakumar Baru; Bhoomeshwar Chiningiri; Santosh Gandhi; Ranjit Kaur
Journal:  Bioorg Med Chem       Date:  2007-01-30       Impact factor: 3.641

7.  Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor.

Authors:  David Parry; Timothy Guzi; Frances Shanahan; Nicole Davis; Deepa Prabhavalkar; Derek Wiswell; Wolfgang Seghezzi; Kamil Paruch; Michael P Dwyer; Ronald Doll; Amin Nomeir; William Windsor; Thierry Fischmann; Yaolin Wang; Martin Oft; Taiying Chen; Paul Kirschmeier; Emma M Lees
Journal:  Mol Cancer Ther       Date:  2010-07-27       Impact factor: 6.261

8.  Development of an assay to screen for inhibitors of tau phosphorylation by cdk5.

Authors:  Jae Suk Ahn; Andrea Musacchio; Marina Mapelli; Jake Ni; Leonard Scinto; Ross Stein; Kenneth S Kosik; Li-An Yeh
Journal:  J Biomol Screen       Date:  2004-03

9.  Design and synthesis of quinolin-2(1H)-one derivatives as potent CDK5 inhibitors.

Authors:  Wenge Zhong; Hu Liu; Matthew R Kaller; Charles Henley; Ella Magal; Thomas Nguyen; Timothy D Osslund; David Powers; Robert M Rzasa; Hui-Ling Wang; Weiya Wang; Xiaoling Xiong; Jiandong Zhang; Mark H Norman
Journal:  Bioorg Med Chem Lett       Date:  2007-08-06       Impact factor: 2.823

10.  GSK-3-selective inhibitors derived from Tyrian purple indirubins.

Authors:  Laurent Meijer; Alexios-Leandros Skaltsounis; Prokopios Magiatis; Panagiotis Polychronopoulos; Marie Knockaert; Maryse Leost; Xiaozhou P Ryan; Claudia Alin Vonica; Ali Brivanlou; Rana Dajani; Claudia Crovace; Cataldo Tarricone; Andrea Musacchio; S Mark Roe; Laurence Pearl; Paul Greengard
Journal:  Chem Biol       Date:  2003-12
View more
  6 in total

1.  Discovery of thienoquinolone derivatives as selective and ATP non-competitive CDK5/p25 inhibitors by structure-based virtual screening.

Authors:  Arindam Chatterjee; Stephen J Cutler; Robert J Doerksen; Ikhlas A Khan; John S Williamson
Journal:  Bioorg Med Chem       Date:  2014-09-28       Impact factor: 3.641

2.  Consensus models for CDK5 inhibitors in silico and their application to inhibitor discovery.

Authors:  Jiansong Fang; Ranyao Yang; Li Gao; Shengqian Yang; Xiaocong Pang; Chao Li; Yangyang He; Ai-Lin Liu; Guan-Hua Du
Journal:  Mol Divers       Date:  2014-12-16       Impact factor: 2.943

3.  Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases.

Authors:  Ernst Schonbrunn; Stephane Betzi; Riazul Alam; Mathew P Martin; Andreas Becker; Huijong Han; Rawle Francis; Ramappa Chakrasali; Sudhakar Jakkaraj; Aslamuzzaman Kazi; Said M Sebti; Christopher L Cubitt; Anthony W Gebhard; Lori A Hazlehurst; Joseph S Tash; Gunda I Georg
Journal:  J Med Chem       Date:  2013-05-06       Impact factor: 7.446

4.  Diaminothiazoles modify Tau phosphorylation and improve the tauopathy in mouse models.

Authors:  Xuemei Zhang; Israel Hernandez; Damien Rei; Waltraud Mair; Joydev K Laha; Madison E Cornwell; Gregory D Cuny; Li-Huei Tsai; Judith A J Steen; Kenneth S Kosik
Journal:  J Biol Chem       Date:  2013-06-04       Impact factor: 5.157

5.  Several human cyclin-dependent kinase inhibitors, structurally related to roscovitine, are new anti-malarial agents.

Authors:  Sandrine Houzé; Nha-Thu Hoang; Olivier Lozach; Jacques Le Bras; Laurent Meijer; Hervé Galons; Luc Demange
Journal:  Molecules       Date:  2014-09-23       Impact factor: 4.411

6.  From on-target to off-target activity: identification and optimisation of Trypanosoma brucei GSK3 inhibitors and their characterisation as anti-Trypanosoma brucei drug discovery lead molecules.

Authors:  Andrew Woodland; Raffaella Grimaldi; Torsten Luksch; Laura A T Cleghorn; Kayode K Ojo; Wesley C Van Voorhis; Ruth Brenk; Julie A Frearson; Ian H Gilbert; Paul G Wyatt
Journal:  ChemMedChem       Date:  2013-06-14       Impact factor: 3.466

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.